Demeetra

Cas-CLOVER delivers more precise genome editing without CRISPR licensing complexity. One license. Full FTO. No royalties.

Cas-CLOVER redefines precision in genome editing. Backed by a single, simple license with full FTO.

𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗞𝗻𝗼𝗰𝗸-𝗜𝗻𝘀 𝗶𝗻 𝗖𝗹𝗲𝗮𝗻𝗖𝘂𝘁 𝗚𝗦 𝗖𝗛𝗢 𝗖𝗲𝗹𝗹𝘀: 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗮𝗯𝗹𝗲 𝗟𝗮𝗻𝗱𝗶𝗻𝗴 𝗣𝗮𝗱 𝗠𝗲𝘁𝗵𝗼𝗱𝘀 𝗳𝗼𝗿 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗖𝗲𝗹𝗹 𝗟𝗶𝗻𝗲 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 We’re excited to share a new white paper demonstrating how Cas-CLOVER enables efficient, precise knock-ins in our CleanCut GS CHO cell host, establishing a robust foundation for next-generation cell line development and bioprocessing. Key results from the study: • Targeted knock-in at the endogenous GAPDH locus delivered >20% stable GFP-only population without selection, indicating highly efficient and precise integration. • Broader applicability confirmed at Chr6-AttP and C12orf35 safe harbor sites, showing Cas-CLOVER performs reliably across multiple genomic contexts. Why this matters for CLD and bioprocessing: ✓ Single-copy or multi-copy insertion strategies ✓ Orthogonal landing pad architectures ✓ Reduced clone-to-clone variability ✓ Lower screening burden and faster CLD timelines ✓ Clearer regulatory pathways compared to random integration Read the full white paper to explore the data: https://lnkd.in/g3fBheCR Ready to accelerate your CLD timelines? Let’s talk about how Cas-CLOVER and CleanCut GS cells can transform your workflow. #CellLineDevelopment #CHOcells #GenomeEngineering #CasCLOVER #Bioprocessing #LandingPads #HDR #SyntheticBiology #BiotechInnovation #CellEngineering

Now Available: On Demand! Our popular webcast seen by of biopharma professionals exploring next-generation solutions for biologics manufacturing, is ready for you to watch anytime. 𝐂𝐚𝐬-𝐂𝐋𝐎𝐕𝐄𝐑 𝐢𝐬 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐠𝐞𝐧𝐞 𝐞𝐝𝐢𝐭𝐢𝐧𝐠, 𝐢𝐭’𝐬 𝐚 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐚𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞. At BioProcess International Fall Digital Week 2025, Demeetra presented: “𝑼𝒏𝒍𝒐𝒄𝒌𝒊𝒏𝒈 𝒕𝒉𝒆 𝑭𝒖𝒕𝒖𝒓𝒆 𝒐𝒇 𝑩𝒊𝒐𝒍𝒐𝒈𝒊𝒄𝒔 𝑴𝒂𝒏𝒖𝒇𝒂𝒄𝒕𝒖𝒓𝒊𝒏𝒈: 𝑪𝒂𝒔-𝑪𝑳𝑶𝑽𝑬𝑹 𝒇𝒐𝒓 𝑩𝒊𝒈 𝑷𝒉𝒂𝒓𝒎𝒂 & 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒅 𝑷𝒊𝒑𝒆𝒍𝒊𝒏𝒆𝒔.” Jack Crawford, CEO, outlines how Cas-CLOVER tackles two challenges facing Big Pharma today: securing robust commercial FTO and achieving scalable, high-efficiency performance beyond CRISPR and ZFNs. Then Corey Brizzee, PhD Brizzee, Ph.D., shares data-driven results on host cell optimization and multiplexed HCP removal—showing how Cas-CLOVER is transforming cell line development from R&D to GMP scale. With flexible, milestone-free licensing, Cas-CLOVER helps biopharma teams accelerate innovation and ROI. Access the full webcast recording here to watch on demand. https://lnkd.in/ebdHgjFv

This event takes place tomorrow, November 18, at 9:00 a.m. ET. Register today! https://lnkd.in/evEVVZuc 𝐓𝐡𝐞 𝐜𝐥𝐞𝐚𝐧 𝐚𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐯𝐞 𝐭𝐨 𝐂𝐑𝐈𝐒𝐏𝐑/𝐂𝐚𝐬𝟗 𝐢𝐬 𝐫𝐞𝐝𝐞𝐟𝐢𝐧𝐢𝐧𝐠 𝐰𝐡𝐚𝐭’𝐬 𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐢𝐧 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠. Join Demeetra at BioProcess International Fall Digital Week on Tuesday, November 18, at 9 AM ET for our two-part presentation: “𝑈𝑛𝑙𝑜𝑐𝑘𝑖𝑛𝑔 𝑡ℎ𝑒 𝐹𝑢𝑡𝑢𝑟𝑒 𝑜𝑓 𝐵𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑠 𝑀𝑎𝑛𝑢𝑓𝑎𝑐𝑡𝑢𝑟𝑖𝑛𝑔: 𝐶𝑎𝑠-𝐶𝐿𝑂𝑉𝐸𝑅 𝑓𝑜𝑟 𝐵𝑖𝑔 𝑃ℎ𝑎𝑟𝑚𝑎 & 𝐴𝑑𝑣𝑎𝑛𝑐𝑒𝑑 𝑃𝑖𝑝𝑒𝑙𝑖𝑛𝑒𝑠.” Register for free to join the live webcast: https://lnkd.in/evEVVZuc In this webcast session, Jack Crawford, CEO, and Corey Brizzee, PhD Brizzee, Ph.D., Director of Gene Editing, reveal how Cas-CLOVER is more than just a precise gene-editing system, it’s a strategic business advantage. We’ll explore how Cas-CLOVER delivers: • True commercial freedom to operate (FTO)—free from burdensome due diligence • Superior scalability and precision compared to ZFNs and older tools • Streamlined licensing with no milestones or royalties • Proven performance in knockout and targeted integration efficiency Join us for insights and live Q&A From discovery to commercial bioproduction, see how Cas-CLOVER empowers biopharma innovators to build future-ready platforms. #BPI2025 #Biologics #GeneEditing #CasCLOVER #Bioprocessing #BigPharma

𝐅𝐫𝐨𝐦 𝐑&𝐃 𝐭𝐨 𝐜𝐆𝐌𝐏, 𝐂𝐚𝐬-𝐂𝐋𝐎𝐕𝐄𝐑 𝐢𝐬 𝐫𝐞𝐝𝐞𝐟𝐢𝐧𝐢𝐧𝐠 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠. Don’t miss our webcast presentation during BioProcess International Fall Digital Week, 𝐖𝐞𝐝𝐧𝐞𝐬𝐝𝐚𝐲, 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟏𝟗, 𝟗 𝐀𝐌 𝐄𝐓: “𝑼𝒏𝒍𝒐𝒄𝒌𝒊𝒏𝒈 𝒕𝒉𝒆 𝑭𝒖𝒕𝒖𝒓𝒆 𝒐𝒇 𝑩𝒊𝒐𝒍𝒐𝒈𝒊𝒄𝒔 𝑴𝒂𝒏𝒖𝒇𝒂𝒄𝒕𝒖𝒓𝒊𝒏𝒈: 𝑪𝒂𝒔-𝑪𝑳𝑶𝑽𝑬𝑹 𝒇𝒐𝒓 𝑩𝒊𝒈 𝑷𝒉𝒂𝒓𝒎𝒂 and 𝑨𝒅𝒗𝒂𝒏𝒄𝒆𝒅 𝑷𝒊𝒑𝒆𝒍𝒊𝒏𝒆𝒔.” We’ll discuss how Cas-CLOVER’s dual-nuclease precision, clear FTO, and licensing model make it a next-generation solution for large-scale therapeutic development. Register to join the live webcast: https://lnkd.in/evEVVZuc #BPI2025 #Biologics #GeneEditing #CasCLOVER #Bioprocessing #BigPharma